Wockhardt Ltd.

WOCKPHARMAHealthcare filings

We hold this company’s filings and have not read the financial statements out of them yet. Every filing on record is listed under filings, and each one opens.

Earnings calls

3 transcript(s)/analyst meet(s) served; 2 document(s) on file are not transcripts (cover letters, duplicates, unresolved) and are excluded. Speaker attribution is shown only where the segmenter attributes ≥ 95% of sentences to management or analysts (0 of 3 documents here); elsewhere sentences render unattributed.

Kind	Date	Period	Served
TRANSCRIPT	20230224	2022-12-31	yes
ANALYST_MEET	20250611	2025-03-31	yes
DUPLICATE	20250611	2025-03-31	no
ANALYST_MEET	20260611	2026-03-31	yes
DUPLICATE	20260611	2026-03-31	no

WOCKPHARMA

files the standard Schedule III statements. Every figure below opens to the filing it was read from; where a figure is not shown, the reason is printed in its place.

Identity


Statement division	general
Scope served	consolidated
Panels on this page	4

Market

No split, bonus or consolidation is on record for this company inside the period this price series covers, so the closes need no adjustment.


Last close	2,287.70
52-week range	1100.3 – 2329.7
Return 1M	20.43%
Return 3M	16.41%
Return 1Y	53.53%
Return 3Y	891.63%
Return 5Y	437.65%
Market capitalisation	not shown — we could not confirm it
Shares outstanding	not shown — we could not confirm it
P/E	not shown — we could not confirm it
P/B	not shown — we could not confirm it
EV/EBITDA	not shown — we could not confirm it

Latest quarter filed — period ending 2026-06-30

In INR crore except per-share figures. `period_id` is the period the filing names for the number; the date beside each cell is when it was filed.


Revenue from operations	929.00
Other income	31.00
Total income	960.00
Cost of materials consumed	233.00
Purchases of stock-in-trade	109.00
Changes in inventories	-22.00
Employee benefit expense	203.00
Finance costs	52.00

Ownership — 2026-06-30, and the change from 2026-03-31

Holder	Per cent	Change
promoter and promoter group	0.49	0.00
institutions foreign	0.07	0.00
institutions domestic	0.09	-0.02
mutual funds	0.07	-0.01
public	0.51	0.00

Documents on file

Class	Most recent	On file
ANALYST_MEET	2026-03-31	2
DUPLICATE	2026-03-31	2
TRANSCRIPT	2022-12-31	1

Financial statements

Filed results, consolidated, in INR crore except per-share figures. Every figure opens to the filing it was read from. Quarterly and annual columns are the periods the filing itself names, never a document date.

Quarterly results, as filed

Line	2022-09-30	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31	2024-03-31	2024-06-30	2024-09-30	2024-12-31	2025-03-31	2025-06-30	2025-09-30	2025-12-31	2026-03-31	2026-06-30
Revenue from operations	679.00	699.00	678.00	644.00	753.00	701.00	700.00	739.00	809.00	721.00	743.00	738.00	782.00	888.00	965.00	929.00
Other income	57.00	2.00	32.00	14.00	24.00	8.00	54.00	30.00	9.00	8.00	15.00	20.00	21.00	25.00	45.00	31.00
Total income	736.00	701.00	710.00	658.00	777.00	709.00	754.00	769.00	818.00	729.00	758.00	758.00	803.00	913.00	1,010.00	960.00
Cost of materials consumed	108.00	134.00	136.00	137.00	179.00	160.00	144.00	150.00	182.00	121.00	159.00	168.00	159.00	170.00	177.00	233.00
Purchases of stock-in-trade	136.00	133.00	125.00	150.00	105.00	150.00	154.00	153.00	150.00	122.00	148.00	140.00	129.00	161.00	156.00	109.00
Changes in inventories	14.00	53.00	45.00	-5.00	3.00	-8.00	-4.00	10.00	-35.00	19.00	-47.00	-44.00	-55.00	-14.00	-15.00	-22.00
Employee benefit expense	163.00	150.00	144.00	154.00	166.00	152.00	157.00	160.00	161.00	164.00	166.00	171.00	186.00	181.00	187.00	203.00
Finance costs	70.00	83.00	76.00	79.00	76.00	77.00	73.00	73.00	73.00	60.00	48.00	48.00	55.00	60.00	50.00	52.00
Depreciation and amortisation	65.00	66.00	56.00	55.00	55.00	55.00	58.00	54.00	55.00	55.00	53.00	56.00	53.00	65.00	53.00	55.00
Other expenses	215.00	184.00	225.00	192.00	228.00	210.00	352.00	175.00	241.00	167.00	253.00	231.00	185.00	213.00	235.00	214.00
Total expenses	771.00	803.00	807.00	762.00	812.00	796.00	934.00	775.00	827.00	708.00	780.00	770.00	712.00	836.00	843.00	844.00
Profit before exceptional items and tax	-35.00	-102.00	-97.00	-104.00	-35.00	-87.00	-180.00	-6.00	-9.00	21.00	-22.00	-12.00	91.00	77.00	167.00	116.00
Exceptional items	-195.00	-3.00	-96.00	-14.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-97.00	0.00	-10.00	22.00	0.00
Profit before tax	-230.00	-105.00	-193.00	-118.00	-35.00	-87.00	-180.00	-6.00	-9.00	21.00	-22.00	-109.00	91.00	67.00	189.00	116.00
Current tax	4.00	2.00	2.00	9.00	2.00	3.00	2.00	2.00	3.00	1.00	1.00	4.00	3.00	6.00	5.00	7.00
Deferred tax	-27.00	-5.00	42.00	9.00	36.00	-4.00	-5.00	8.00	4.00	0.00	22.00	-5.00	6.00	0.00	20.00	2.00
Tax expense	-23.00	-3.00	44.00	18.00	38.00	-1.00	-3.00	10.00	7.00	1.00	23.00	-1.00	9.00	6.00	25.00	9.00
Profit for the period	-207.00	-102.00	-237.00	-136.00	-73.00	-86.00	-177.00	-16.00	-16.00	20.00	-45.00	-108.00	82.00	61.00	164.00	107.00
Profit attributable to owners	-189.00	-96.00	-208.00	-134.00	-77.00	-83.00	-169.00	-14.00	-22.00	14.00	-25.00	-90.00	78.00	59.00	166.00	106.00
Profit attributable to non-controlling interests	-18.00	-6.00	-29.00	-2.00	4.00	-3.00	-8.00	-2.00	6.00	6.00	-20.00	-18.00	4.00	2.00	-2.00	1.00
Other comprehensive income	-65.00	141.00	22.00	-1.00	-20.00	67.00	-40.00	-3.00	89.00	-70.00	56.00	148.00	93.00	28.00	150.00	14.00
Total comprehensive income	-272.00	39.00	-215.00	-137.00	-93.00	-19.00	-217.00	-19.00	73.00	-50.00	11.00	40.00	175.00	89.00	314.00	121.00
Earnings per share, basic	-13.15	-6.62	-14.37	-9.28	-5.37	-5.75	-11.64	-0.95	-1.47	0.91	-1.57	-5.53	4.81	3.61	10.23	6.55
Earnings per share, diluted	-13.15	-6.62	-14.37	-9.28	-5.37	-5.75	-11.64	-0.95	-1.47	0.91	-1.57	-5.53	4.81	3.61	10.22	6.55

Annual results, as filed

Line	2019-03-31	2020-03-31	2021-03-31	2022-03-31	2023-03-31	2024-03-31	2025-03-31	2026-03-31
Revenue from operations	4,158.00	2,844.00	2,708.00	3,230.00	2,651.00	2,798.00	3,012.00	3,373.00
Other income	21.00	39.00	132.00	20.00	122.00	83.00	62.00	111.00
Total income	4,179.00	2,883.00	2,841.00	3,250.00	2,773.00	2,881.00	3,074.00	3,484.00
Cost of materials consumed	854.00	622.00	682.00	612.00	518.00	620.00	612.00	674.00
Purchases of stock-in-trade	919.00	508.00	580.00	568.00	509.00	559.00	573.00	586.00
Changes in inventories	41.00	74.00	-127.00	87.00	84.00	-14.00	-53.00	-128.00
Employee benefit expense	937.00	743.00	763.00	749.00	637.00	629.00	651.00	725.00
Finance costs	265.00	276.00	249.00	299.00	302.00	305.00	254.00	213.00
Depreciation and amortisation	166.00	224.00	246.00	247.00	251.00	223.00	217.00	227.00
Other expenses	1,297.00	778.00	873.00	916.00	802.00	965.00	836.00	864.00
Total expenses	4,480.00	3,225.00	3,266.00	3,478.00	3,103.00	3,287.00	3,090.00	3,161.00
Profit before exceptional items and tax	-300.00	-342.00	-426.00	-228.00	-330.00	-406.00	-16.00	323.00
Exceptional items	0.00	0.00	-142.00	-183.00	-294.00	-14.00	0.00	-85.00
Profit before tax	-300.00	-342.00	-568.00	-411.00	-624.00	-420.00	-16.00	238.00
Current tax	9.00	-45.00	-121.00	38.00	12.00	16.00	7.00	18.00
Deferred tax	-93.00	-159.00	-151.00	-170.00	-15.00	36.00	34.00	21.00
Tax expense	-84.00	-204.00	-272.00	-132.00	-3.00	52.00	41.00	39.00
Profit for the period	-217.00	-43.00	689.00	-279.00	-621.00	-472.00	-57.00	199.00
Profit attributable to owners	-195.00	-69.00	686.00	-244.00	-559.00	-463.00	-47.00	213.00
Profit attributable to non-controlling interests	-22.00	26.00	3.00	-35.00	-62.00	-9.00	-10.00	-14.00
Other comprehensive income	9.00	101.00	-4.00	-27.00	78.00	6.00	71.00	419.00
Total comprehensive income	-208.00	57.00	685.00	-306.00	-543.00	-466.00	14.00	618.00
Earnings per share, basic	-17.58	-6.25	61.95	-20.24	-38.79	-32.05	-3.02	13.12
Earnings per share, diluted	-17.58	-6.29	61.56	-20.24	-38.79	-32.05	-3.02	13.10

Balance sheet, as filed

Line	2022-09-30	2023-03-31	2023-09-30	2024-03-31	2024-09-30	2025-03-31	2025-09-30	2026-03-31
Total assets	7,834.00	7,683.00	7,420.00	7,649.00	7,588.00	8,135.00	8,533.00	8,615.00
Non-current assets	5,572.00	5,475.00	5,383.00	5,465.00	5,580.00	5,566.00	5,728.00	5,918.00
Current assets	2,118.00	1,914.00	1,739.00	2,073.00	1,904.00	2,465.00	2,701.00	2,606.00
Property, plant and equipment	2,235.00	2,022.00	1,929.00	1,875.00	1,806.00	1,718.00	1,673.00	1,618.00
Capital work-in-progress	395.00	414.00	419.00	434.00	481.00	513.00	583.00	671.00
Goodwill	849.00	945.00	933.00	953.00	991.00	977.00	995.00	1,028.00
Other intangible assets	89.00	75.00	58.00	53.00	50.00	41.00	160.00	145.00
Inventories	748.00	658.00	635.00	640.00	657.00	725.00	866.00	887.00
Trade receivables	816.00	797.00	714.00	618.00	695.00	661.00	536.00	588.00
Cash and cash equivalents	187.00	90.00	54.00	505.00	143.00	112.00	177.00	217.00
Total equity and liabilities	7,834.00	7,683.00	7,420.00	7,649.00	7,588.00	8,135.00	8,533.00	8,615.00
Equity	3,837.00	3,662.00	3,432.00	3,662.00	3,713.00	4,657.00	4,876.00	5,281.00
Equity share capital	72.00	72.00	72.00	77.00	77.00	81.00	81.00	81.00
Other equity	3,422.00	3,282.00	3,053.00	3,282.00	3,318.00	4,272.00	4,486.00	4,859.00
Total liabilities	3,997.00	4,021.00	3,988.00	3,987.00	3,875.00	3,478.00	3,657.00	3,334.00
Non-current liabilities	751.00	586.00	1,303.00	1,196.00	1,495.00	1,436.00	1,921.00	1,712.00
Current liabilities	3,246.00	3,435.00	2,685.00	2,791.00	2,380.00	2,042.00	1,736.00	1,622.00
Borrowings, non-current	243.00	224.00	968.00	891.00	1,219.00	1,211.00	1,669.00	1,518.00
Borrowings, current	1,613.00	1,663.00	1,035.00	1,221.00	935.00	648.00	654.00	607.00
Trade payables	740.00	867.00	800.00	766.00	677.00	592.00	587.00	563.00

Cash flow, as filed

Line	2022-09-30	2023-03-31	2023-09-30	2024-03-31	2024-09-30	2025-03-31	2025-09-30	2026-03-31
Net cash from operating activities	61.00	153.00	104.00	219.00	32.00	-22.00	189.00	390.00
Net cash from investing activities	-103.00	-125.00	-88.00	-137.00	-247.00	-783.00	-417.00	-241.00
Net cash from financing activities	-141.00	-315.00	-50.00	334.00	-147.00	409.00	297.00	-54.00
Purchase of property, plant and equipment	9.00	42.00	12.00	59.00	48.00	94.00	70.00	136.00
Net increase in cash	-183.00	-280.00	-36.00	415.00	-362.00	-393.00	69.00	105.00
con:CFO.BEFORE_TAX	69.00	164.00	122.00	249.00	-4.00	-53.00	201.00	411.00
con:INTEREST_RECEIVED.OPERATING	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
con:INTEREST_PAID.OPERATING	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
con:DIVIDENDS_RECEIVED.OPERATING	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
con:TAX_PAID.OPERATING	8.00	11.00	18.00	30.00	-36.00	-31.00	12.00	21.00
con:CF_OTHER.OPERATING	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
con:INVESTMENTS_PURCHASED	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
con:INVESTMENTS_SOLD	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
con:PPE_DISPOSALS	0.00	79.00	0.00	66.00	317.00	10.00	14.00	50.00
con:CF_INVESTING.SUBSIDIARIES_SOLD	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
con:CF_INVESTING.SUBSIDIARIES_ACQUIRED	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
con:CF_INVESTING.JV_SOLD	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
con:CF_INVESTING.JV_ACQUIRED	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

Who owns it

The shareholding pattern filed with the exchange every quarter, as a series. Percentages are of total shares. Each figure names the filing it was read from and the date it was filed.

Holder	2023-09-30	2023-12-31	2024-03-26	2024-03-31	2024-06-30	2024-09-30	2024-11-11	2024-12-31	2025-03-31	2025-06-30	2025-09-30	2025-12-31	2026-03-31	2026-06-30
Promoter and promoter group	55.14	54.93	51.60	51.60	51.99	51.99	49.09	49.09	49.09	49.09	0.49	0.49	0.49	0.49
Domestic institutions	0.22	0.34	4.83	4.83	4.45	5.09	9.88	9.82	10.59	11.01	0.11	0.11	0.11	0.09
Mutual funds	—	—	—	—	—	—	—	—	—	8.02	0.08	0.08	0.08	0.07
Insurance companies	0.00	0.00	0.00	0.00	0.00	0.00	0.50	0.47	0.51	0.46	0.01	0.00	0.00	0.00
Foreign institutions	3.02	4.17	5.59	5.49	5.93	6.70	6.62	6.54	6.81	7.29	0.07	0.07	0.07	0.07
Government	—	—	—	—	—	—	—	—	—	0.02	0.00	0.00	0.00	0.00
Public	44.86	45.07	48.40	48.40	48.01	48.01	50.91	50.91	50.91	50.91	0.51	0.51	0.51	0.51
Non-institutional	41.61	40.56	37.97	38.06	37.61	36.21	34.39	34.53	33.50	32.60	0.33	0.33	0.33	0.34
Shares outstanding	144094573	144101473	153400936	153400936	153400936	153409546	162472319	162472319	162485569	162485569	162492169	162492169	162492169	162492169

Related parties

Transactions with related parties as disclosed to the exchange for the period ending 2024-09-30, by counterparty, largest first. Amounts are as filed. Each row names the filing and the date it was filed.

Counterparty	Relationship	Type	Amount in the period	Transactions
Wockhardt Bio Ag	Subsidiary	Any other transaction, Sale of goods or services	3,141,500,000.00	7
Wockahrdt UK Limited	Subsidiary	Any other transaction, Sale of goods or services	3,102,700,000.00	4
CP Pharmaceuticals Limited	Step down subsidiary	Any other transaction, Purchase of goods or services	2,462,600,000.00	13
Pinewood Laboratories Limited	Step down subsidiary	Any other transaction, Dividend received, Loan, Purc	635,600,000.00	14
Carol Info Services Limited	Enterprises over which Key Manager	Any other transaction, Purchase of goods or services	450,400,000.00	5
Themisto Trustee Company Private Limited	Enterprises over which Key Manager	Any other transaction, Loan	400,100,000.00	3
Wockhardt Bio (R) LLC	Step down subsidiary	Any other transaction, Sale of goods or services	379,100,000.00	10
Wockahrdt USA LLC	Step down subsidiary	Any other transaction, Loan, Sale of goods or servic	314,200,000.00	7
Callirhoe Trustee Company Pvt Ltd	Enterprises over which Key Manager	Any other transaction	199,000,000.00	2
Khorakiwala Holdings and Investments Private Limited	Enterprises over which Key Manager	Any other transaction, Loan	167,300,000.00	6
Wockhardt Infrastructure Development Limited	Wholly Owned Subsidiary	Any other transaction, Purchase of goods or services	157,400,000.00	7
Palanpur Holdings and Investments Private Limited	Enterprises over which Key Manager	Any other transaction, Loan, Purchase of goods or se	155,800,000.00	7
Ananke Trustee Company Pvt Ltd	Enterprises over which Key Manager	Any other transaction, Loan	128,200,000.00	2
Merind Limited	Enterprises over which Key Manager	Any other transaction	49,500,000.00	5
Dr. Habil Khorakiwala Education and Health Foundation ( Trus	Enterprises over which Key Manager	Any other transaction	13,600,000.00	2

What management said

Every earnings call we hold for this company, read in full. Prepared remarks are separated from the question-and-answer session and every paragraph names who said it and on which page. These are management’s own words, not filed figures.

Date	Quarter	Who spoke
2026-06-11	Q4FY26	DIRECTOR – WOCKHARDT LIMITED, Dilini Quadros:, WOCKHARDT LIMITED, – WOCKHARDT LIMITED	Read the call
2025-06-11	Q4FY25	DIRECTOR – WOCKHARDT LIMITED, WOCKHARDT LIMITED	Read the call

Some earlier announcements under this heading are covering letters only — no transcript was attached.

What they said about it, quarter by quarter

Topic	Q4FY25	Q4FY26
Capex	—	My question is, can you give us some sort of projections on what you're looking in terms of capex and as well as revenue to be had, while pursuing the…
Capital allocation	—	And then we again had some challenge, we divested some of our businesses over a period of time.
Debt and cash	So if you see the debt that we had, which is a net debt which was 882 in '22 has gone down to 64 in '25 and that's where we have reduced our external …	Plus, they span a different time horizon, cash flow cycle, and that gives a sustainability and stability to the entire operating model.
Demand	One is our diabetes biosimilar business, which includes insulin glargine and other products that we are developing and in the pipeline.	So, we have two products commercialized and five more products in the pipeline, which include Aspart, RN 30/70, Degludec, Degludec Aspart, and Semaglu…
Guidance	We have also last year initiated the strategy of expansion of EMROK in other indications, as well as to other specialties and customers in India and w…	But that will come much later, and we expect European approval by end of the year.
Margin	June 05, 2025 our sales in the last year has grown by 5%, EBITDA has grown by 67% and our EBITDA margin has expanded by 500 basis points from 9% to 14…	Three years back, our EBITDA margin was about 5.4%, which has now increased to 18.6%.
People	—	The commercial partner essentially is somebody who will help us with the logistics of hiring a sales force, whilst we will select the people, they wil…
Pricing	What we are targeting is a market of 96 million prescriptions to the relevant doctor specialties which has an addressable market of INR10,800 crores a…	—
Revenue growth	Some of the other positives that we have achieved in our organization in the last year has been growth of various businesses across.	Our top line is at INR3,373 crores, with an EBITDA of about INR630 crores, and EBITDA growth of about 51%, and our profitability before tax at INR238 …